235 related articles for article (PubMed ID: 14614647)
1. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
Holstein A; Egberts EH
Exp Clin Endocrinol Diabetes; 2003 Oct; 111(7):405-14. PubMed ID: 14614647
[TBL] [Abstract][Full Text] [Related]
2. Clinical characterisation of severe hypoglycaemia--a prospective population-based study.
Holstein A; Plaschke A; Egberts EH
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):364-9. PubMed ID: 14520604
[TBL] [Abstract][Full Text] [Related]
3. [Hypoglycemia--a dreaded complication of diabetes].
Bjørgaas M
Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2441-4. PubMed ID: 11475234
[TBL] [Abstract][Full Text] [Related]
4. Severe hypoglycaemia in type 1 diabetes: impact of the renin-angiotensin system and other risk factors.
Pedersen-Bjergaard U
Dan Med Bull; 2009 Nov; 56(4):193-207. PubMed ID: 19939337
[TBL] [Abstract][Full Text] [Related]
5. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy.
Barnett AH
Curr Med Res Opin; 2010 Jun; 26(6):1333-42. PubMed ID: 20370379
[TBL] [Abstract][Full Text] [Related]
6. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes.
Barnett AH; Cradock S; Fisher M; Hall G; Hughes E; Middleton A
Int J Clin Pract; 2010 Jul; 64(8):1121-9. PubMed ID: 20236369
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
[TBL] [Abstract][Full Text] [Related]
8. Balancing risk and benefit with oral hypoglycemic drugs.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
[TBL] [Abstract][Full Text] [Related]
9. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
10. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes?
Frier BM
Int J Clin Pract Suppl; 2002 Jul; (129):12-9. PubMed ID: 12166599
[TBL] [Abstract][Full Text] [Related]
11. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Raskin P
Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
[TBL] [Abstract][Full Text] [Related]
12. [Clinically important effects of oral antidiabetic drug interactions].
Drzewoski J; Kopff B
Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985
[TBL] [Abstract][Full Text] [Related]
13. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
14. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older.
Greco D; Pisciotta M; Gambina F; Maggio F
Exp Clin Endocrinol Diabetes; 2010 Apr; 118(4):215-9. PubMed ID: 20072965
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of type 2 diabetes. Critical evaluation of oral antidiabetic drugs].
Landgraf R
MMW Fortschr Med; 2000 May; 142(21):33-7. PubMed ID: 10872292
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
Prescrire Int; 2001 Feb; 10(51):9-11. PubMed ID: 11503861
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
18. Metformin and the sulphonylureas: the comparative risk.
Campbell IW
Horm Metab Res Suppl; 1985; 15():105-11. PubMed ID: 3935560
[TBL] [Abstract][Full Text] [Related]
19. Utilization of antidiabetic drugs in Hong Kong: relation to the common occurrence of antidiabetic drug-induced hypoglycemia amongst acute medical admissions and the relative prevalence of NIDDM.
Chan TY; Lee KK; Chan AW; Critchley JA
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):43-6. PubMed ID: 8688996
[TBL] [Abstract][Full Text] [Related]
20. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
